Spina Bifida in-Utero Market Report 2026

The spina bifida in-utero market size has grown strongly in recent years. It will grow from $2.65 billion in 2025 to $2.89 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to advancements in prenatal imaging, growth in high-risk pregnancy care, clinical research in fetal surgery, specialist hospital expansion, awareness of congenital disorders.

The spina bifida in-utero market size is expected to see strong growth in the next few years. It will grow to $4.06 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to minimally invasive fetal surgery adoption, improved surgical success rates, expansion of maternal-fetal centers, technological innovation in instruments, clinical guideline evolution. Major trends in the forecast period include fetal surgery technique refinement, early prenatal screening adoption, multidisciplinary fetal care teams, specialized surgical instruments, improved maternal-fetal outcomes.

The expansion of healthcare facilities is expected to drive the growth of the spina bifida in-utero market in the coming years. Healthcare facilities refer to the essential physical infrastructure, systems, and resources required to deliver effective medical services. The growth of healthcare infrastructure is supported by advancements in medical technology, as innovations such as telemedicine, robotic surgery, and AI-driven diagnostics necessitate upgraded facilities, specialized equipment, and enhanced healthcare delivery systems to improve patient outcomes and efficiency. Healthcare facilities support spina bifida in-utero care by providing access to evidence-based therapies, trained medical professionals, and innovative treatment options, all of which contribute to better healing outcomes and improved quality of life for patients. For example, according to the American Hospital Association, a US-based non-profit organization, in January 2024, the United States had 6,120 hospitals. Therefore, the expansion of healthcare infrastructure is fueling the growth of the spina bifida in-utero market.

Key companies in the spina bifida in-utero market are establishing innovative centers, such as specialized surgery centers, to integrate advanced imaging and minimally invasive techniques for fetal interventions. A surgery center is a facility where surgical procedures are performed on an outpatient basis, eliminating the need for hospital admission. For instance, in January 2025, Wadia Hospital, an India-based healthcare institution, launched a center offering fetal surgery for open spina bifida. The facility combines cutting-edge surgical techniques with a multidisciplinary approach, enabling early intervention that can reduce complications and improve long-term outcomes for affected infants. The center focuses on enhancing surgical precision and patient care, providing promising development for families facing challenges associated with open spina bifida.

In March 2024, Lilavati Hospital, an India-based multi-specialty healthcare institution, partnered with the Medical University of Silesia. The collaboration aims to establish a fetal surgery department to provide advanced in-utero treatment for birth defects such as spina bifida, enhancing prenatal healthcare and patient outcomes. The Medical University of Silesia, based in Poland, provides advanced fetal surgery techniques and in-utero treatment for congenital conditions.

Major companies operating in the spina bifida in-utero market are Mayo Clinic, GE HealthCare, UC San Francisco, Children’s Health, Memorial Hermann Health System, Oregon Health & Science University, Seattle Children's, Texas Children’s, Children's Hospital of Philadelphia, UW Health, UC Davis, UCSF Health, Burjeel Hospital, UT Physicians, Riley Children's Health, Yale Medicine, Focused Ultrasound Foundation, Boston Children’s Hospital, Johns Hopkins Hospital, Cleveland Clinic, Mount Sinai Health System, Stanford Health Care.

North America was the largest region in the spina bifida in utero market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spina bifida in-utero market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the spina bifida in-utero market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the spina bifida in-utero market by increasing the cost of imported surgical instruments, imaging systems, fetal surgery devices, and sterile consumables. Specialty hospitals and fetal care centers in Asia-Pacific and Europe are most impacted due to reliance on international medical technology suppliers. These higher costs can raise procedural expenses and slow the adoption of advanced prenatal surgical techniques. However, tariffs are encouraging localized production of surgical equipment and medical supplies, improving long-term treatment availability.

The spina bifida in-utero market research report is one of a series of new reports that provides spina bifida in-utero market statistics, including spina bifida in-utero industry global market size, regional shares, competitors with a spina bifida in-utero market share, detailed spina bifida in-utero market segments, market trends and opportunities, and any further data you may need to thrive in the spina bifida in-utero industry. This spina bifida in-utero market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Spina bifida in-utero refers to a prenatal surgical procedure performed to correct spina bifida, a neural tube defect in which the spine and spinal cord do not develop properly. This surgery, conducted before birth, aims to reduce complications such as hydrocephalus and improve mobility and neurological outcomes. By closing the defect early, it helps protect the exposed spinal cord from further damage and can enhance the child’s quality of life compared to postnatal repair.

The main types of spina bifida in-utero include myelomeningocele, meningocele, and occulta. Myelomeningocele is the most severe form, in which the spinal cord and meninges protrude through an opening in the spine. Diagnosis methods include ultrasound, magnetic resonance imaging (MRI), and amniocentesis, while treatment options include prenatal surgery, postnatal surgery, and medication management. These procedures are utilized by end users such as hospitals, specialty clinics, and ambulatory surgical centers.

The spina bifida in-utero market consists of revenues earned by entities providing services such as physical therapy planning, genetic counseling, and multidisciplinary team support. The market value includes the value of related goods sold by the service provider or included within the service offering. The spina bifida in-utero market also includes sales of sales of anesthesia and maternal support equipment, fetal monitoring devices, and biodegradable adhesives and sealants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.